Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.

Hdl Handle:
http://hdl.handle.net/10147/230177
Title:
Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.
Authors:
Romero-Ortuno, Roman; O'Shea, Diarmuid
Affiliation:
St Vincent's University Hospital, Department of Medicine for the Elderly, Elm Park, Dublin 4, Ireland. romeror@tcd.ie
Citation:
Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. 2012, 41 (2):250-4 Age Ageing
Journal:
Age and ageing
Issue Date:
Mar-2012
URI:
http://hdl.handle.net/10147/230177
DOI:
10.1093/ageing/afr165
PubMed ID:
22156597
Abstract:
the primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin. CHA(2)DS(2)-VASc estimates annual stroke rates for untreated AF patients, which are reduced by 60% with warfarin and by 20% with aspirin. HAS-BLED estimates annual rates of major bleeding on warfarin. The latter risk with aspirin is 0.5-1.2% per year.
Item Type:
Article
Language:
en
MeSH:
Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Decision Trees; Hemorrhage; Humans; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin
ISSN:
1468-2834

Full metadata record

DC FieldValue Language
dc.contributor.authorRomero-Ortuno, Romanen_GB
dc.contributor.authorO'Shea, Diarmuiden_GB
dc.date.accessioned2012-06-22T11:00:14Z-
dc.date.available2012-06-22T11:00:14Z-
dc.date.issued2012-03-
dc.identifier.citationAspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. 2012, 41 (2):250-4 Age Ageingen_GB
dc.identifier.issn1468-2834-
dc.identifier.pmid22156597-
dc.identifier.doi10.1093/ageing/afr165-
dc.identifier.urihttp://hdl.handle.net/10147/230177-
dc.description.abstractthe primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin. CHA(2)DS(2)-VASc estimates annual stroke rates for untreated AF patients, which are reduced by 60% with warfarin and by 20% with aspirin. HAS-BLED estimates annual rates of major bleeding on warfarin. The latter risk with aspirin is 0.5-1.2% per year.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Age and ageingen_GB
dc.subject.meshAnticoagulants-
dc.subject.meshAspirin-
dc.subject.meshAtrial Fibrillation-
dc.subject.meshDecision Support Techniques-
dc.subject.meshDecision Trees-
dc.subject.meshHemorrhage-
dc.subject.meshHumans-
dc.subject.meshPatient Selection-
dc.subject.meshPrimary Prevention-
dc.subject.meshRisk Assessment-
dc.subject.meshRisk Factors-
dc.subject.meshStroke-
dc.subject.meshTreatment Outcome-
dc.subject.meshWarfarin-
dc.titleAspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.en_GB
dc.typeArticleen
dc.contributor.departmentSt Vincent's University Hospital, Department of Medicine for the Elderly, Elm Park, Dublin 4, Ireland. romeror@tcd.ieen_GB
dc.identifier.journalAge and ageingen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.